Latest Period
Q4 2025
Security Snapshot
ImmunityBio, Inc. - Common Stock, par value $0.0001 per share (IBRX) Institutional Ownership
CUSIP: 45256X103
13F Institutional Holders and Ownership History from Q1 2019 to Q1 2026
Institutions Reporting
264
Shares (Excl. Options)
167,430,604
Price
$1.98
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- IBRX on Nasdaq
- Shares outstanding
- 1,124,549,707
- Price per share
- $7.30
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 167,430,604
- Total reported value
- $331,779,142
- % of total 13F portfolios
- 0%
- Share change
- +24,672,143
- Value change
- +$45,120,859
- Number of holders
- 264
- Price from insider filings
- $7.30
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- IBRX - ImmunityBio, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 45256X103.
- 264 institutions reported positions in Q4 2025.
- 1 significant owner is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 264 to 125 between Q4 2025 and Q1 2026.
- Reported value moved from $331,779,142 to $71,621,687.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 264 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 45256X103?
CUSIP 45256X103 identifies IBRX - ImmunityBio, Inc. - Common Stock, par value $0.0001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 45256X103:
Significant Owners of ImmunityBio, Inc. - Common Stock, par value $0.0001 per share (IBRX) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Cambridge Equities, LP | 66% | -3.8% | $4,406,356,855 | +$9,487,063 | 745,576,456 | +0.22% | Patrick Soon-Shiong | 23 Feb 2026 |
As of 31 Dec 2025, 264 institutional investors reported holding 167,430,604 shares of ImmunityBio, Inc. - Common Stock, par value $0.0001 per share (IBRX). This represents 15% of the company’s total 1,124,549,707 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of ImmunityBio, Inc. - Common Stock, par value $0.0001 per share (IBRX) together control 13% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| VANGUARD GROUP INC | 2.9% | 32,777,257 | +19% | 0% | $64,898,969 |
| BlackRock, Inc. | 2.3% | 25,601,219 | +29% | 0% | $50,690,414 |
| STATE STREET CORP | 1.5% | 16,455,703 | +45% | 0% | $32,582,292 |
| JANE STREET GROUP, LLC | 1.3% | 14,224,224 | +11% | 0.03% | $28,163,963 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.7% | 7,920,178 | +15% | 0% | $15,684,103 |
| GOLDMAN SACHS GROUP INC | 0.55% | 6,152,684 | +439% | 0% | $12,182,314 |
| MORGAN STANLEY | 0.45% | 5,106,214 | +51% | 0% | $10,110,303 |
| TWO SIGMA INVESTMENTS, LP | 0.42% | 4,717,843 | +81% | 0.01% | $9,341,329 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.32% | 3,654,499 | +38% | 0.01% | $7,235,908 |
| Woodline Partners LP | 0.31% | 3,446,540 | -35% | 0.03% | $6,824,149 |
| AlphaCore Capital LLC | 0.27% | 3,000,544 | +0.4% | 0.13% | $5,941,077 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.22% | 2,501,666 | +8.8% | 0% | $4,953,299 |
| BARCLAYS PLC | 0.22% | 2,444,163 | +163% | 0% | $4,839,444 |
| BANK OF AMERICA CORP /DE/ | 0.21% | 2,382,503 | +44% | 0% | $4,717,356 |
| TANG CAPITAL MANAGEMENT LLC | 0.21% | 2,333,333 | 0% | 0.23% | $4,619,999 |
| NORTHERN TRUST CORP | 0.2% | 2,230,112 | +11% | 0% | $4,415,622 |
| UBS Group AG | 0.18% | 1,995,607 | +19% | 0% | $3,951,301 |
| Voleon Capital Management LP | 0.13% | 1,514,586 | +9218% | 0.06% | $2,998,880 |
| Squarepoint Ops LLC | 0.13% | 1,494,713 | +48% | 0.01% | $2,959,532 |
| Skandinaviska Enskilda Banken AB (publ) | 0.12% | 1,324,871 | 0% | 0.01% | $2,616,620 |
| RENAISSANCE TECHNOLOGIES LLC | 0.11% | 1,231,770 | +21% | 0% | $2,438,905 |
| JPMORGAN CHASE & CO | 0.11% | 1,219,879 | +15% | 0% | $2,415,361 |
| TWO SIGMA ADVISERS, LP | 0.1% | 1,142,256 | +871% | 0% | $2,261,667 |
| Bank of New York Mellon Corp | 0.08% | 882,327 | +16% | 0% | $1,747,007 |
| Clearwater Capital Advisors, LLC | 0.08% | 845,084 | -0.16% | 0.14% | $1,673,267 |
Institutional Holders of ImmunityBio, Inc. - Common Stock, par value $0.0001 per share (IBRX) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 9,481,679 | $71,621,687 | +$25,248,618 | $7.67 | 125 |
| 2025 Q4 | 167,430,604 | $331,779,142 | +$45,120,859 | $1.98 | 264 |
| 2025 Q3 | 149,650,186 | $368,148,509 | +$61,432,781 | $2.46 | 258 |
| 2025 Q2 | 124,100,473 | $327,790,828 | +$117,120,227 | $2.64 | 236 |
| 2025 Q1 | 79,547,067 | $239,251,849 | -$5,452,987 | $3.01 | 205 |
| 2024 Q4 | 82,639,855 | $211,622,425 | +$33,803,467 | $2.56 | 193 |
| 2024 Q3 | 68,558,924 | $255,147,599 | +$21,750,911 | $3.72 | 172 |
| 2024 Q2 | 61,630,296 | $389,584,078 | -$21,451,973 | $6.32 | 188 |
| 2024 Q1 | 66,215,691 | $355,583,288 | +$50,300,460 | $5.37 | 157 |
| 2023 Q4 | 57,525,605 | $288,814,721 | +$55,491,609 | $5.02 | 141 |
| 2023 Q3 | 49,844,823 | $84,098,555 | +$17,530,681 | $1.69 | 128 |
| 2023 Q2 | 38,816,393 | $107,856,591 | -$8,601,646 | $2.78 | 108 |
| 2023 Q1 | 46,154,939 | $83,993,343 | -$34,886,181 | $1.82 | 141 |
| 2022 Q4 | 49,991,144 | $253,404,020 | +$54,026,855 | $5.07 | 134 |
| 2022 Q3 | 39,497,245 | $196,456,912 | +$32,509,458 | $4.97 | 117 |
| 2022 Q2 | 33,071,782 | $123,053,543 | -$11,174,770 | $3.72 | 124 |
| 2022 Q1 | 35,583,839 | $199,726,649 | +$5,888,206 | $5.61 | 135 |
| 2021 Q4 | 34,419,957 | $209,314,595 | +$13,197,046 | $6.08 | 127 |
| 2021 Q3 | 31,920,475 | $310,877,791 | +$41,850,403 | $9.74 | 118 |
| 2021 Q2 | 27,315,269 | $390,084,556 | +$155,924,275 | $14.28 | 115 |
| 2021 Q1 | 15,930,587 | $378,240,945 | +$377,213,945 | $23.74 | 112 |
| 2020 Q4 | 100 | $1,000 | $10.00 | 1 | |
| 2020 Q3 | 100 | $1,000 | $10.00 | 1 | |
| 2020 Q2 | 100 | $1,000 | $10.00 | 1 | |
| 2020 Q1 | 100 | $1,000 | $10.00 | 1 | |
| 2019 Q4 | 100 | $1,000 | $10.00 | 1 | |
| 2019 Q3 | 100 | $1,000 | $10.00 | 1 | |
| 2019 Q2 | 100 | $1,000 | $10.00 | 1 | |
| 2019 Q1 | 100 | $1,000 | $10.00 | 1 |